

Cite this: *Chem. Sci.*, 2022, 13, 13094

All publication charges for this article have been paid for by the Royal Society of Chemistry

## Enol-mediated delivery of H<sub>2</sub>Se from $\gamma$ -keto selenides: mechanistic insight and evaluation†

Rynne A. Hankins, Molly E. Carter, Changlei Zhu, Chen Chen and John C. Lukesh,  
|||  \*

Like hydrogen sulfide (H<sub>2</sub>S), its chalcogen congener, hydrogen selenide (H<sub>2</sub>Se), is an emerging molecule of interest given its endogenous expression and purported biological activity. However, unlike H<sub>2</sub>S, detailed investigations into the chemical biology of H<sub>2</sub>Se are limited and little is known about its innate physiological functions, cellular targets, and therapeutic potential. The obscurity surrounding these fundamental questions is largely due to a lack of small molecule donors that can effectively increase the bioavailability of H<sub>2</sub>Se through their continuous liberation of the transient biomolecule under physiologically relevant conditions. Driven by this unmet demand for H<sub>2</sub>Se-releasing moieties, we report that  $\gamma$ -keto selenides provide a useful platform for H<sub>2</sub>Se donation *via* an  $\alpha$ -deprotonation/ $\beta$ -elimination pathway that is highly dependent on both pH and alpha proton acidity. These attributes afforded a small library of donors with highly variable rates of release (higher alpha proton acidity = faster selenide liberation), which is accelerated under neutral to slightly basic conditions—a feature that is unique and complimentary to previously reported H<sub>2</sub>Se donors. We also demonstrate the impressive anticancer activity of  $\gamma$ -keto selenides in both HeLa and HCT116 cells in culture, which is likely to stimulate additional interest and research into the biological activity and anticancer effects of H<sub>2</sub>Se. Collectively, these results indicate that  $\gamma$ -keto selenides provide a highly versatile and effective framework for H<sub>2</sub>Se donation.

Received 23rd June 2022  
Accepted 19th October 2022

DOI: 10.1039/d2sc03533b

rsc.li/chemical-science

## Introduction

Gasotransmitters are a small family of endogenously expressed, gaseous signaling molecules that include nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H<sub>2</sub>S).<sup>1–3</sup> For admittance into this select group, specific criteria must be met.<sup>4</sup> The molecule must exist as a gas and be able to freely permeate cellular membranes. Moreover, its endogenous production should be enzymatically regulated, ensuring its ability to carry out specific biological functions at physiologically relevant concentrations. Lastly, it should elicit its physiological effects while acting on well-defined biological targets.

Hydrogen sulfide is the most recent member, with its inclusion first being suggested in the early 2000s.<sup>4,5</sup> H<sub>2</sub>S is primarily produced in mammalian systems *via* the enzymatic catabolism of sulfur-containing amino acids.<sup>6–9</sup> With particularly high expression levels in the central nervous system, endogenous H<sub>2</sub>S functions as a neuromodulator in the brain by enhancing NMDA receptor-mediated responses.<sup>10,11</sup> It also plays an important role in vasodilation and blood pressure regulation

through its activation of K<sub>ATP</sub> channels.<sup>12</sup> Additionally, H<sub>2</sub>S displays impressive antioxidative and cytoprotective effects stemming from its activation of the Keap1-Nrf-2 pathway, which leads to the upregulation of antioxidant enzymes.<sup>13</sup> The underlying mechanism behind these, and other, H<sub>2</sub>S-mediated pharmacological effects is believed to involve the persulfidation of protein thiols (protein–SSH)—an important posttranslational modification that impacts protein structure and function.<sup>14</sup>

Similar to H<sub>2</sub>S, its chalcogen congener, hydrogen selenide (H<sub>2</sub>Se), is beginning to attract the attention of the scientific community as an endogenously expressed, biologically active gas. Sulfur and selenium possess similar physical and chemical properties. However, given its increased size and polarizability, reactions involving selenium tend to be significantly faster than analogous reactions involving sulfur.<sup>15–17</sup> Therefore, it is conceivable that H<sub>2</sub>Se may promote comparable protein modifications (protein–SSeH) that influence cellular activity, even at significantly lower concentrations.

Hydrogen selenide is chiefly produced from the reduction of dietary inorganic selenium salts (selenate and selenite) and from the enzymatic breakdown of selenium-containing amino acids (selenomethionine) (Fig. 1).<sup>18–20</sup> Once formed, H<sub>2</sub>Se is used to generate other selenium-containing biomolecules, including important redox-active proteins, like thioredoxin reductase (TrxR) and glutathione peroxidase (GPx), that rely on

Department of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, NC 27101, USA. E-mail: lukeshjc@wfu.edu

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2sc03533b>






Fig. 1 A simplified schematic of endogenous  $\text{H}_2\text{Se}$  production in mammalian systems. Glutathione (GSH), glutathione disulfide (GSSG), glutaredoxin (Grx), glutathione reductase (GR), thioredoxin (Trx), thioredoxin reductase (TrxR), transsulfuration pathway (TSP), selenocysteine  $\beta$ -lyase (SCLY), selenophosphate synthetase (SPS), and selenocysteine synthase (SecS).

selenocysteine, nature's 21st amino acid, to maintain cellular redox homeostasis.<sup>15,21</sup> Therefore, given its gaseous nature (in its diprotic form), its bioactivity, and the strict enzymatic control over its biosynthesis,  $\text{H}_2\text{Se}$  already satisfies several gasotransmitter requirements, sparking some to suggest its inclusion as the fourth official gaseous signaling molecule in mammalian systems.<sup>22</sup> While there is some evidence to support this claim, a clear description of its redox biochemistry remains poorly defined.

In many respects,  $\text{H}_2\text{Se}$  is perceived similarly to how  $\text{H}_2\text{S}$  was at the turn of the 20th century. Historically dismissed as a toxic and foul-smelling gas,<sup>23</sup> in the past two decades the immense physiological and pathophysiological effects of  $\text{H}_2\text{S}$  were largely uncovered thanks to the introduction of small molecule donors that were used to modulate cellular concentrations by effectively mimicking the natural, enzymatic production of  $\text{H}_2\text{S}$  over a prolonged period of time.<sup>24–27</sup> Conversely, analogous donors for exploring the biological prevalence and significance of  $\text{H}_2\text{Se}$  are extremely scarce, which is why its innate physiological functions, molecular targets, and participation in redox signaling remain a mystery.

To meet this unmet demand, previously reported  $\text{H}_2\text{S}$  donors are being reengineered to deliver  $\text{H}_2\text{Se}$  in a controlled and sustained manner.<sup>28–31</sup> Among the first to be examined was a hydrolysis-based donor reported by Pluth and co-workers.<sup>29</sup> Taking inspiration from the widely studied  $\text{H}_2\text{S}$  donor **GY4137**,<sup>32</sup> they generated an analogous slow-release donor that was shown to effectively liberate  $\text{H}_2\text{Se}$  through hydrolytic P=Se bond cleavage in buffered solutions (**TDN1042**, Fig. 2). Consistent with a hydrolysis-based mechanism, the authors noted a significant increase in hydrolysis at more acidic pH values.

Complimentary to this initial report, we sought to cultivate a new class of slow-release donors that operate *via* an alternative mechanism such that their rate of  $\text{H}_2\text{Se}$  delivery would be enhanced under neutral to slightly basic conditions. By applying lessons learned from earlier reported and successful




Fig. 2 Complimentary  $\text{H}_2\text{Se}$  donors promoted by acid (a) and base (b).

$\text{H}_2\text{S}$  donors,<sup>33</sup> we hypothesized that  $\gamma$ -keto selenides (**1**, Fig. 2) would meet this requirement by releasing  $\text{H}_2\text{Se}$  through an  $\alpha$ -deprotonation/ $\beta$ -elimination pathway that would be dependent on alpha proton acidity, thereby providing a series of related donors with highly tunable rates of  $\text{H}_2\text{Se}$  release.

## Results discussion

Our investigations commenced by treating 3-chloropropiophenone with sodium selenide to afford **1** (Fig. 2) in moderate yield (see ESI† for details). Once in hand, we sought to investigate the propensity of **1** to release selenide in buffered water.

A current challenge in  $\text{H}_2\text{Se}$  donor development is the lack of streamlined analytical techniques for effectively quantifying the delivery of hydrogen selenide over time. Since the chemical shift of the methylene protons of our donor (**1**) are easily distinguishable from those of the enone byproduct (**2**), we reasoned that  $^1\text{H}$  NMR would provide a convenient analytical method for monitoring the conversion of **1** to **2** and, thus, the release of selenide.

Indeed, in a 1 : 1 mixture of  $\text{CD}_3\text{CN}$  and deuterated phosphate buffer (50 mM, pD 7.4), the clean conversion of **1** to **2** was observed by  $^1\text{H}$  NMR as the intensity of the protons alpha to selenium slowly decreased over the course of the experiment while the intensity of the terminal enone protons simultaneously increased (Fig. 3a). Using 1,4-dioxane as an internal standard, we were able to monitor the concentrations of both **1** and **2** throughout the course of the reaction, confirming that the consumption of **1** tracks nicely with the production of **2** (Fig. 3b). While the slow-release time is likely due, in part, to the reversible nature of the  $\beta$ -elimination, this, along with the clean formation of **2**, unambiguously confirms not only the ability, but the mechanism by which **1** releases  $\text{H}_2\text{Se}$  in buffer.

Additional qualitative evidence for selenide release from **1** was inferred from an observation that a noticeable red film was always present inside of our NMR tubes upon the completion of our kinetics experiments. In aqueous buffer,  $\text{H}_2\text{Se}$  is known to rapidly oxidize to  $\text{Se}^0$ ,<sup>19</sup> which is what we suspected this was. To confirm, the red film was isolated, treated with excess triphenylphosphine, and analyzed by  $^{31}\text{P}$  NMR (Fig. 3c). As predicted,






Fig. 3 (a and b) Time-course for the conversion of ketone **1** (2.5 mM) into enone **2** at ambient temperature and in a 1 : 1 mixture of CD<sub>3</sub>CN and deuterated phosphate buffer (50 mM, pD 7.4). 1,4-Dioxane was used as an internal standard to determine the concentration of **1** and **2** at different time points. All reactions were performed in triplicate and plotted as the mean ± STDEV. (c) Resultant <sup>31</sup>P NMR spectrum from the reaction between triphenylphosphine (PPh<sub>3</sub>) and precipitated selenium (Se<sup>0</sup>) from the decomposition of **1** in solution.

the formation of triphenylphosphine selenide was cleanly observed, confirming the identity of the red residue as Se<sup>0</sup>.<sup>34</sup>

We also note that during the course of the reaction, we did observe a very small amount of diselenide formation, which is easily attributable to the propensity of the released selenol (from a single β-elimination) to oxidize in a nonreducing

environment. This perhaps suggests that the first and second elimination steps are not necessarily coupled (as depicted in Fig. 2). Nevertheless, we confirmed that under the same reaction conditions, the ensuing diselenide also cleanly eliminates to form enone **2** while delivering a payload of H<sub>2</sub>Se<sub>2</sub>, which is known to quickly disproportionate to H<sub>2</sub>Se and Se<sup>0</sup> (Fig. S2†).<sup>35</sup>

Having confirmed that the reaction mechanism proceeds through a β-elimination pathway, we suspected that the rate of H<sub>2</sub>Se release would be highly influenced by pH. To examine this, additional kinetic studies were run in deuterium buffer at a pD of 6 and 8.5 (Fig. 4). As anticipated, the formation of **2** was found to be greatly accelerated in a more basic environment. Conversely, its production was noticeably inhibited under slightly acidic conditions. These results suggest that γ-keto selenides are endowed with pH-control over their release of selenide, which may prove useful in certain applications.

After demonstrating the pH dependence on enone formation and selenide donation, we rationalized that the introduction of simple structural modifications that tuned α-proton acidity would provide a series of related donors with highly variable rates of H<sub>2</sub>Se liberation.

Our library of donors is depicted in Fig. 5a and is arranged in the order of increasing α-proton acidity (3 < 4 ≈ 1 < 5). For these experiments we employed benzyl bromide as an electrophilic trap to confirm selenide release and to render the reaction irreversible. Once again, a 1 : 1 mixture of CD<sub>3</sub>CN and deuterated phosphate buffer (50 mM, pD 7.4) was employed, and the reaction progress was monitored by <sup>1</sup>H NMR using 1,4-dioxane as an internal standard.

Both donor consumption (Fig. 5b) and the formation of **6** were examined throughout the course of the reaction and the results are summarized in Fig. 5c. In general, alpha proton acidity was found correlate perfectly with both the rate of selenide release and the ensuing yield of **6**. For example, **1** and **4** were found to have similar rates of decomposition (*t*<sub>1/2</sub> = 3.9 h and 4.2 h, respectively), while giving rise to similar yields of **6** (59% and 40%, respectively). Being an amide with significantly decreased alpha proton acidity, donor **3** was found to be by far




Fig. 4 Effect of pD on enone (**2**) formation and selenide donation from **1** (2.5 mM). Reactions were run at ambient temperature and in a 1 : 1 mixture of CD<sub>3</sub>CN and deuterated phosphate buffer (50 mM). All reactions were performed in triplicate and plotted as the mean ± STDEV.




Fig. 5 (a) Library of donors arranged in the order of increasing alpha proton acidity (5 being the most acidic). (b) Time-course for the decomposition of donors (1 mM) in the presence of benzyl bromide (4.4 mM). Reactions were run at ambient temperature and in a 1 : 1 mixture of CD<sub>3</sub>CN and deuterated phosphate buffer (50 mM, pD 7.4). 1,4-Dioxane was used as an internal standard to determine concentrations at various time points. Curves were fitted to obtain pseudo-first-order rate constants and half-lives ( $t_{1/2}$ ). All reactions were performed in triplicate and plotted as the mean  $\pm$  STDEV. (c) Comparisons between donor half-life and the yield of **6** after a 24 hour incubation period. <sup>a</sup>Combined yield of mono and diselenide derivatives of benzyl bromide after a 7 hour incubation period.

the most stable ( $t_{1/2} = 22.3$  h), as expected, and its yield of **6** was exceptionally low, indicating very little selenide release. Conversely donor **5**, being far and away the most acidic, was discovered to decompose almost instantly in buffer ( $t_{1/2} = 0.3$  h), while engendering the highest yield of **6** in just a few hours. It is interesting to note that in the case of **5**, both the mono and diselenide derivatives of benzyl bromide were observed by NMR (Fig. S3<sup>†</sup>), and its reported yield (95%) was calculated from the combined concentrations of both species. Contrarily, only the monoselenide derivative (**6**) was observed for reactions between donors **1**, **3**, and **4** and benzyl bromide.

To unambiguously confirm H<sub>2</sub>Se release from  $\gamma$ -keto selenides, we performed an additional trapping experiment where donor **1** was incubated in a tube separate from the electrophilic trap.<sup>29</sup> For this experiment, we employed iodoacetamide as the electrophilic agent as the ensuing product from its trapping of volatilized H<sub>2</sub>Se would be easily discernible by high-resolution mass spectrometry. To accomplish this, the solution of **1** was acidified and sparged with argon to facilitate H<sub>2</sub>Se liberation into the headspace of the tube. There, its transfer through a carefully placed cannula needle would provide access to the separate, trapping solution. Using high-resolution mass spectrometry, the expected selenide product was clearly visible in the trapping solution, confirming the ability of **1** to directly release H<sub>2</sub>Se (Fig. S5<sup>†</sup>).

In search of further evidence for H<sub>2</sub>Se release from  $\gamma$ -keto selenides, but under more biologically relevant conditions, we incubated **1** (100  $\mu$ M) in a redox buffer consisting of glutathione (180  $\mu$ M) and glutathione disulfide (20  $\mu$ M) at room temperature and in an ammonium bicarbonate buffer (0.1 M, pH 7.4) (Fig. 6). In this setting, we surmised that both H<sub>2</sub>Se and/or **7**—which would form from a single  $\beta$ -elimination—would have the potential to form glutathioneselenol (GSSeH), which could then react further under the reaction conditions to generate the more stable selenodiglutathione (GSSeSG) species that we might be able to observe directly by mass spectrometry. Indeed, when an aliquot of the reaction mixture was analyzed by direct infusion MS, the mass corresponding to GSSeSG (GSSeSG + Na<sup>+</sup>) was clearly visible and appeared to form in an appreciable amount,




Fig. 6 Confirmation of selenodiglutathione formation, a known H<sub>2</sub>Se precursor, upon exposure of **1** (100  $\mu$ M) to a biologically relevant redox buffer consisting of glutathione (180  $\mu$ M) and glutathione disulfide (20  $\mu$ M) in ammonium bicarbonate buffer (0.1 M, pH 7.4).



especially given its relative abundance to that of glutathione disulfide ( $\text{GSSG} + \text{H}^+$ ) (Fig. 6). This result unequivocally confirms the ability of  $\gamma$ -keto selenides, like **1**, to produce  $\text{H}_2\text{Se}$  under biological conditions, since it establishes their capacity to form biologically relevant reactive selenium species that are known to be in equilibrium with  $\text{H}_2\text{Se}$  (Fig. 1).

Lastly, we aimed to evaluate this new series of donors within a cellular environment. The anticancer activity of  $\text{H}_2\text{Se}$  has been recorded in earlier studies and appears to be quite promising. Depending on cellular conditions,  $\text{H}_2\text{Se}$  can function as either a potent reductant or pro-oxidant, inducing reductive or oxidative stress, respectively, in cancer cells leading to apoptosis.<sup>36</sup> Given that cancer cells exhibit a higher intracellular pH compared to normal cells,<sup>37</sup> we speculated that  $\gamma$ -keto selenides, and their more efficient release of selenide under more basic conditions (Fig. 4), might be especially advantageous at inhibiting cancer cell growth.

To examine this premise, we screened compounds **1**, **3**, **4**, and **5** for growth inhibition activity against HeLa (human cervical cancer) and HCT116 (human colon cancer) cells in

culture (Fig. 7). Not surprisingly, compound **3**—which was found to be completely stable in buffer for months at a time and only liberated trace amounts of selenide, even while in the presence of benzyl bromide—was completely inactive in both cell lines. In stark contrast, compounds **1**, **4**, and **5** each displayed low micromolar activity against both HeLa and HCT116 cells, which is consistent with the anticancer activity of previously reported  $\text{H}_2\text{Se}$  donors.<sup>36,38</sup>

As a key control, we also synthesized and assessed the anticancer activity of **4EC**, an oxygen congener of **4**, to help differentiate the cancer cell growth inhibitory of effects of  $\text{H}_2\text{Se}$  from the other organic components of the reaction. As expected, **4EC** displayed similar activity to that of **3** in both HeLa and HCT116 cells in culture, suggesting that it is, in fact, the released selenide from **1**, **4**, and **5** that is likely to be responsible for the promising anticancer activity of these compounds.

It is also interesting to note that **5**, which releases  $\text{H}_2\text{Se}$  at more than an order of magnitude faster than both **1** and **4** (Fig. 5), was about two-fold less potent. Similar to the anticancer activity of slow-releasing  $\text{H}_2\text{S}$  donors,<sup>39</sup> this result is intriguing and perhaps suggests that the slow and sustained decomposition of **1** and **4**, which results in cells being exposed to continuous low levels of  $\text{H}_2\text{Se}$  for a prolonged period of time, is more beneficial to cancer cell growth inhibition than is the instantaneous surge in selenide concentration that is likely afforded by **5**.

## Conclusions

In closing, we report that  $\gamma$ -keto selenides offer a valuable and highly versatile platform for pH-dependent,  $\text{H}_2\text{Se}$  donation. Detailed mechanistic studies were carried out by  $^1\text{H}$  NMR, which confirm the mechanism of release as an  $\alpha$ -deprotonation/ $\beta$ -elimination sequence. As such, accelerated rates of selenide liberation were observed at higher pH and with donors that possess more acidic alpha protons. We further established  $\text{H}_2\text{Se}$  donation under more biologically relevant conditions by verifying the formation of selenodiglutathione upon  $\gamma$ -keto selenide exposure to a glutathione/glutathione disulfide redox buffer. Impressive anticancer activity was also observed with this class of donors in both HeLa and HCT116 cells in culture. Overall, these results establish  $\gamma$ -keto selenide-based donors as a valuable addition to the investigative toolkit for probing the chemical biology and therapeutic value of  $\text{H}_2\text{Se}$  and their introduction is likely to spark additional interest and research into this burgeoning field of study.

## Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Author contributions

RAH: synthesis and characterization of compounds, mechanistic studies, data acquisition and analysis, and manuscript preparation. MEC: assisted with synthesis and characterization




Fig. 7 Cell growth inhibition of **1**, **3**, **4**, **5**, and **4EC** (ether control) in HeLa (human cervical cancer) and HCT116 (human colon cancer) cells in culture. IC<sub>50</sub> values were determined after a 24 hour incubation period and are reported as the average  $\pm$  STDEV from three independent assays.



of compounds and data acquisition. CZ: cytotoxicity studies and data analysis. CC: assisted with cytotoxicity studies and data analysis. JCL: project conceptualization and supervision, acquisition of funding, data analysis, and manuscript preparation and editing.

## Conflicts of interest

The authors declare no conflicts of interest.

## Acknowledgements

The authors thank the National Science Foundation (Grant No. 2143826) for financial support of this work.

## Notes and references

- G. Yang, A. Sener, Y. Ji, Y. Pei and M. D. Pluth, *Oxid. Med. Cell. Longevity*, 2016, **2016**, 1–2.
- A. Papapetropoulos, R. Foresti and P. Ferdinandy, *Br. J. Pharmacol.*, 2015, **172**, 1395–1396.
- R. Wang, *Proc. Natl. Acad. Sci.*, 2012, **109**, 8801–8802.
- R. Wang, *FASEB J.*, 2002, **16**, 1792–1798.
- M. M. Gadalla and S. H. Snyder, *J. Neurochem.*, 2010, **113**, 14–26.
- X. Cao, L. Ding, Z. Xie, Y. Yang, M. Whiteman, P. K. Moore and J.-S. Bian, *Antioxid. Redox Signaling*, 2019, **31**, 1–38.
- H. Kimura, *Amino Acids*, 2011, **41**, 113–121.
- E. W. Miles and J. P. Kraus, *J. Biol. Chem.*, 2004, **279**, 29871–29874.
- I. Ishii, N. Akahoshi, H. Yamada, S. Nakano, T. Izumi and M. Suematsu, *J. Biol. Chem.*, 2010, **285**, 26358–26368.
- K. Abe and H. Kimura, *J. Neurosci.*, 1996, **16**, 1066–1071.
- H. Kimura, *Biochem. Biophys. Res. Commun.*, 2000, **267**, 129–133.
- W. Zhao, *EMBO J.*, 2001, **20**, 6008–6016.
- J. W. Calvert, S. Jha, S. Gundewar, J. W. Elrod, A. Ramachandran, C. B. Pattillo, C. G. Kevil and D. J. Lefer, *Circ. Res.*, 2009, **105**, 365–374.
- M. R. Filipovic, J. Zivanovic, B. Alvarez and R. Banerjee, *Chem. Rev.*, 2018, **118**, 1253–1337.
- H. J. Reich and R. J. Hondal, *ACS Chem. Biol.*, 2016, **11**, 821–841.
- D. Steinmann, T. Nauser and W. H. Koppenol, *J. Org. Chem.*, 2010, **75**, 6696–6699.
- J. C. Lukesh, B. VanVeller and R. T. Raines, *Angew. Chem., Int. Ed.*, 2013, **52**, 12901–12904.
- R. F. Burk and K. E. Hill, *Annu. Rev. Nutr.*, 2015, **35**, 109–134.
- K. Cupp-Sutton and M. Ashby, *Antioxidants*, 2016, **5**, 42.
- C. M. Weekley and H. H. Harris, *Chem. Soc. Rev.*, 2013, **42**, 8870.
- V. M. Labunskyy, D. L. Hatfield and V. N. Gladyshev, *Physiol. Rev.*, 2014, **94**, 739–777.
- M. Kuganesan, K. Samra, E. Evans, M. Singer and A. Dyson, *Intensive Care Med. Exp.*, 2019, **7**, 71.
- N. Fiedler, H. Kippen, P. Ohman-Strickland, J. Zhang, C. Weisel, R. Laumbach, K. Kelly-McNeil, K. Olejeme and P. Liroy, *Environ. Health Perspect.*, 2008, **116**, 78–85.
- C. M. Levinn, M. M. Cerda and M. D. Pluth, *Antioxid. Redox Signaling*, 2020, **32**, 96–109.
- C. R. Powell, K. M. Dillon and J. B. Matson, *Biochem. Pharmacol.*, 2018, **149**, 110–123.
- S. Xu, A. Hamsath, D. L. Neill, Y. Wang, C. Yang and M. Xian, *Chem. – Eur. J.*, 2019, **25**, 4005–4016.
- Y. Zheng, X. Ji, K. Ji and B. Wang, *Acta Pharm. Sin. B*, 2015, **5**, 367–377.
- A. Kharma, A. Misak, M. Grman, V. Brezova, L. Kurakova, P. Baráth, C. Jacob, M. Chovanec, K. Ondrias and E. Domínguez-Álvarez, *New J. Chem.*, 2019, **43**, 11771–11783.
- T. D. Newton and M. D. Pluth, *Chem. Sci.*, 2019, **10**, 10723–10727.
- T. D. Newton, S. G. Bolton, A. C. Garcia, J. E. Chouinard, S. L. Golledge, L. N. Zakharov and M. D. Pluth, *J. Am. Chem. Soc.*, 2021, **143**, 19542–19550.
- X. Kang, H. Huang, C. Jiang, L. Cheng, Y. Sang, X. Cai, Y. Dong, L. Sun, X. Wen, Z. Xi and L. Yi, *J. Am. Chem. Soc.*, 2022, **144**, 3957–3967.
- L. Li, M. Whiteman, Y. Y. Guan, K. L. Neo, Y. Cheng, S. W. Lee, Y. Zhao, R. Baskar, C.-H. Tan and P. K. Moore, *Circulation*, 2008, **117**, 2351–2360.
- Y. Zhao, A. K. Steiger and M. D. Pluth, *Angew. Chem., Int. Ed.*, 2018, **57**, 13101–13105.
- R. Kumar, S. Kumar, M. K. Pandey, V. S. Kashid, L. Radhakrishna and M. S. Balakrishna, *Eur. J. Inorg. Chem.*, 2018, **2018**, 1028–1037.
- B. L. Shaw and L. A. K. Stavely, *Inorganic Hydrides: The Commonwealth and International Library: Chemistry Division*, Elsevier Science, Kent, 2014.
- X. Pan, X. Song, C. Wang, T. Cheng, D. Luan, K. Xu and B. Tang, *Theranostics*, 2019, **9**, 1794–1808.
- M. Damaghi, J. W. Wojtkowiak and R. J. Gillies, *Front. Physiol.*, 2013, **4**, 1–10.
- A. Krakowiak, L. Czernek, M. Pichlak and R. Kaczmarek, *Int. J. Mol. Sci.*, 2022, **23**, 607.
- Z. W. Lee, J. Zhou, C.-S. Chen, Y. Zhao, C.-H. Tan, L. Li, P. K. Moore and L.-W. Deng, *PLoS One*, 2011, **6**, e21077.

